Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA). Our recent study imply that the neuroprotective effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, DELP was used to investigate the effect on acute ischemic stroke receiving endovascular treatment.

Inclusion Criteria:

• Age ≥18 years;
• acute anterior circulatory cerebral infarction with large vessel occlusion;
• NIHSS≥6 before endovascular treatment;
• good recanalization (TICI 2b-3);
• time from onset to groin puncture is less than 8 hours;
• time from recanalization to DELP is less than 2 hours;
• Premorbid mRS 0 or 1;
• Signed informed consent.

Exclusion Criteria:

• poor recanalization (TICI 1-2a);
• Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ <100000/mm3;
• Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
• Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
• Previous allergy to heparin or calcium;
• hypoproteinemia;
• Unsuitable for this clinical studies assessed by researcher.

IPD will be shared in request after the trial finish and will include study protocol, statistical analysis plan.